Sign In
Buy CFRX
$0.0500
+0 (+0%)
At Close: Mar 04, 2024
ContraFect Reports First Quarter 2020 Financial Results and Provides Business Update
11:30am, Friday, 15'th May 2020
ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modal
ContraFect Announces Four Abstracts Published in the 30th ECCMID Abstract Book
11:30am, Monday, 11'th May 2020
YONKERS, N.Y., May 11, 2020 -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents.
Stocks To Watch: Jobs Report, Virtual Conferences And Blue Chips On Tap
01:09pm, Saturday, 02'nd May 2020
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
AIM ImmunoTech’s CEO to Present at Maxim’s Infectious Disease Virtual Conference
10:30am, Wednesday, 29'th Apr 2020
OCALA, FL / ACCESSWIRE / April 29, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral dis
ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modal
Analyzing Kezar Life Sciences (NASDAQ:KZR) & ContraFect (NASDAQ:CFRX)
05:30am, Monday, 20'th Apr 2020
ContraFect (NASDAQ:CFRX) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of t
ContraFect to Chair and Participate in Virtual Superbugs & Superdrugs 2020 Conference
09:00am, Monday, 30'th Mar 2020
YONKERS, N.Y., March 30, 2020 -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents.
ContraFect's (CFRX) "Buy" Rating Reiterated at Maxim Group
10:34am, Monday, 23'rd Mar 2020
Maxim Group reiterated their buy rating on shares of ContraFect (NASDAQ:CFRX) in a research note published on Thursday morning, AnalystRatings.com reports. The firm currently has a $22.00 target price
CFRX: Interim Futility Analysis for Phase 3 DISRUPT Trial Once 60% Enrolled…
10:15am, Monday, 23'rd Mar 2020
By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update Update on Phase 3 DISRUPT Trial In January, 2020, ContraFect Corp. (NASDAQ:CFRX) announced the first patient had been
We're Keeping An Eye On ContraFect's (NASDAQ:CFRX) Cash Burn Rate
01:01pm, Saturday, 21'st Mar 2020
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
ContraFect Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
11:00am, Wednesday, 18'th Mar 2020
YONKERS, N.Y., March 18, 2020 -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents.
ContraFect to Present at FDA Workshop on Advancing Animal Models for Antibacterial Drug Development
12:00pm, Wednesday, 04'th Mar 2020
ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modal
Analysts Offer Insights on Healthcare Companies: ContraFect (CFRX) and United Therapeutics (UTHR)
05:42pm, Monday, 24'th Feb 2020
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on ContraFect (CFRX) and United Therapeutics (UTHR).
Analysts Offer Insights on Healthcare Companies: ContraFect (NASDAQ: CFRX) and United Therapeutics (NASDAQ: UTHR)
05:42pm, Monday, 24'th Feb 2020
Companies in the
Healthcare sector have received a lot of coverage today as analysts
weigh in on ContraFect (
CFRX
–
Research Report
) and United Therapeutics (
UTHR
–
Research Report
).
ContraFec
GILD, GOLD among premarket gainers
02:17pm, Monday, 24'th Feb 2020
NGM Biopharmaceuticals (NASDAQ:NGM) +67% after aldafermin phase 2 results.NanoViricides (NYSEMKT:NNVC) +39% on drugmakers working on coronavirus.Enlivex Therapeutics (NASDAQ:ENLV) +37% after disclo
